Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study

[1]  A. Farmer,et al.  Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study , 2022, Nature Medicine.

[2]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[3]  A. Farmer,et al.  TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol , 2020, BMJ Open.

[4]  J. Dennis.  Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment , 2020, Diabetes.

[5]  Ali Kazemi Karyani,et al.  Patient and physician preferences for type 2 diabetes medications: a systematic review , 2019, Journal of Diabetes & Metabolic Disorders.

[6]  H. Itoh,et al.  Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial , 2019, Current medical research and opinion.

[7]  J. Tyson,et al.  Treating Hypertension in Children With n-of-1 Trials , 2019, Pediatrics.

[8]  B. Shields,et al.  Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach , 2018, Clinical Epidemiology.

[9]  B. Shields,et al.  Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data , 2018, Diabetes Care.

[10]  F. Strollo,et al.  A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence , 2018, Expert opinion on drug safety.

[11]  K. Khunti,et al.  Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis , 2016, Diabetes, obesity & metabolism.

[12]  M. Dworak,et al.  Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study , 2015, Therapeutic advances in endocrinology and metabolism.

[13]  V. Montori,et al.  Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. , 2015, The Journal of clinical endocrinology and metabolism.

[14]  Tanjala S. Purnell,et al.  Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review , 2014, Diabetes Care.

[15]  T. Vilsbøll,et al.  Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment , 2011, Current medical research and opinion.

[16]  P. Raskin,et al.  Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. , 2011, Diabetes technology & therapeutics.

[17]  R. Kravitz,et al.  N-of-1 Trials in the Medical Literature: A Systematic Review , 2011, Medical care.

[18]  N. Schork,et al.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? , 2011, Personalized medicine.

[19]  Paul Glasziou,et al.  Using N-of-1 Trials to Improve Patient Management and Save Costs , 2010, Journal of General Internal Medicine.

[20]  F. Johnson,et al.  Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose‐lowering agents , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[21]  D. Matthews,et al.  N of 1 trials in diabetes: making individual therapeutic decisions , 2008, Diabetologia.

[22]  Chris B Del Mar,et al.  Using n-of-1 trials as a clinical tool to improve prescribing. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.

[23]  M. Korytkowski,et al.  A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. , 2003, Clinical therapeutics.

[24]  Stephen Senn,et al.  Cross-over trials in clinical research , 1993 .

[25]  L. Matza,et al.  Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER) , 2019, Diabetes, obesity & metabolism.

[26]  P R Jackson,et al.  Cross over trials. , 1996, British journal of clinical pharmacology.